ABSTRACT
OBJECTIVE: To evaluate the effect of short-term intensive therapy on blood glucose control, BETA-cell function, and blood lipid levels in newly diagnosed type 2 diabetic patients. METHODS: Out-patients with newly diagnosed type 2 diabetic patients were enrolled for intensive treatment with sulfonylureas and metformin for 12 weeks, and the therapeutic effect was evaluated. RESULTS: After the intensive treatment, FPG, 2 hPG, and HbA1c decreased significantly (P<0.01); HOMA-IR decreased and HOMA-B increased significantly (P<0.01), and TG, CHOL, LDL decreased significantly (P<0.01) after the treatment. CONCLUSION: Short-term intensive treatment with glimepiride combined with metformin is safe and effective in newly diagnosed type 2 diabetic patients with HbA1c>9%.
Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Metformin/therapeutic use , Sulfonylurea Compounds/therapeutic use , Drug Therapy, Combination , Female , Humans , Male , Treatment OutcomeABSTRACT
OBJECTIVE: To clone the recombinant human islet neogenesis-associated protein (rhINGAP) gene for its secretory expression in Pichia pastoris. METHODS: INGAP gene was amplified with PCR and inserted between Xho I and EcoR I downstream sites of the alpha factor of the recombinant plasmid alpha/pUC18. The fusion gene of alpha factor and INGAP was subsequently inserted between BamH I and EcoR I sites of the plasmid pPIC9K of P. pastoris. After confirmation with restriction enzyme digestion and sequencing, the positive recombinant plasmid that integrated INGAP gene was linearized with Sal I digestion and transformed into the yeast host strain GS115 through electroporation. The yeast transformants that harbored the INGAP gene with high copies were selected with the auxotroph medium and G418, followed then by PCR verification of the positive transformants, from which the expression of recombinant human INGAP was induced with methanol as the only carbone source. The antigenic activity of the desired protein was then detected using Western blotting and enzyme-linked immunosorbent assay (ELISA). RESULTS AND CONCLUSION: The recombinant expression plasmid INGAP/pPIC9K was successfully constructed, and 3 positive transformants were obtained. The expressed protein showed good antigenic activity as confirmed by Western blotting and ELISA.
Subject(s)
Antigens, Neoplasm/metabolism , Biomarkers, Tumor/metabolism , Lectins, C-Type/metabolism , Pichia/genetics , Recombinant Proteins/metabolism , Antigens, Neoplasm/genetics , Biomarkers, Tumor/genetics , Blotting, Western , Cloning, Molecular , Enzyme-Linked Immunosorbent Assay , Gene Expression , Humans , Islets of Langerhans/metabolism , Lectins, C-Type/genetics , Pancreatitis-Associated Proteins , Pichia/metabolismABSTRACT
OBJECTIVE: To understand the association between plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G polymorphism and type 2 diabetic nephropathy (DN) in Chinese Han patients in Guangdong Province. METHODS: PAI-1 gene 4G/5G polymorphism was analyzed in 26 normal individuals, 77 patients with type 2 diabetic nephropathy and 70 type 2 diabetic patients without nephropathy (DNN) by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: The 4G/4G genotype frequencies of PAI-1 gene were higher in DN than in DNN patients (0.390 vs 0.171, chi(2)=13.008, P<0.01), with the odds ratio (OR) of 1.447 (95% confidence interval: 0.533-3.934, P<0.05) in comparison with 5G/5G genotypes between the 2 patient groups. The 4G allele frequencies of PAI-1 gene were similar in DN and DNN groups (0.57 vs 0.51, chi(2)=1.22, P>0.05). CONCLUSION: The PAI-1 4G/4G genotype is associated with increased risk for type 2 DN the Chinese Han population in Guangdong Province, and type 2 diabetic patients with 4G/4G PAI-1 genotype are more likely to develop DN than those with 5G/5G PAI-1 genotype.